



NanoDrug
Delivery GmbH

Helping Drugs Reach Their Full Potential



Protected Drug



Flexible Composition




Precise Delivery




Better Efficacy

Drugs Almost Never Reach Their Full Potential

Only 8 of 100 drug candidates are approved*



Loss 1: R&D investments




Efficacy Stability Tolerability


Loss 2: Therapy Efficacy

*Biotechnology Innovation Organization (BIO), Informa Pharma Intelligence & QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011-2020. February 2021.


Drugs Fail Before Reaching Their Target




Low solubility ❌




Low stability ❌



Selectivity ❌




The Answer: Drug Delivery




Drug

+



“Packaging”

=



Nanoparticle


Low Drug-Load

Complex Structure

Little Flexibility



Our Nanoparticles




Drugs

+




Packaging

=



Hybrid-Nanoparticle



Dual-Hybrid-Nanoparticle


Unique patent-protected structure

Unlocking 'hard-to-deliver' drugs

Drug Combinations




Our Nanoparticles



Drug is only bound /dissolved




vs.




Drug is integral part of the structure



Solution: Nanoparticles



Versatility and High Drug Load



Versatility

Neurological disorders

Cannabinoids

publication in preparation

Multiple sclerosis

Betamethasone

J Control Release 2020, 319, 360-370

Bacterial infections

Clindamycin

ACS Omega 2018, 3, 8589-8594

Colonrectal cancer

Irinotecan + FdUMP

Small Sci. 2024, 2400196(1-14)

Viral infections


Foscarnet

ACS Biomater Sci Eng. 2022, 8, 1596-1603

Pancreatic cancer

SN38 + FdUMP


Nanoscale 2024, 16, 14853




Case-Study: Pancreatic Cancer

Model-System: Gemcitabine (GEM)


Biodistribution



Resistant Cells




Business Model: Outlicensing



Market Potential

105 **209**
Bn \$ (2025) Bn \$ (2034)
CAGR 7.91%



Notable deals between pharma and drug delivery companies:



AbbVie / Capstan: 2.1
Bn \$ (2025)



Sangamo / Eli Lilly: up to:
1.4 Bn \$ in milestones
(2025)



DelSiTech / Tolmar: up
200 Mi \$ in milestones
(2024)

Fundraising



~€500,000

SEED INVESTMENT SOUGHT

Use of funds

- Product validation
- Go-to-market
- Team expansion



Leveraged by grants



HTI BioIntelligence

from Oct 2026

✓ Secured



Horizon Europe

from end of 2026

✓ Secured



Additional grants

We plan to submit further grant applications.



Use of funds



Strategic milestones



End 2026

First customer projects
+ non-dilutive grant



End of 2027

First license option /
partnership



2028

Full data package
(toxicity, stability, kinetics)

Team

Develops NP Platform



Dr. David Rudolph
Founder & Managing Director



Prof. Dr. Claus Feldmann
Founder



Soon to be filled
Lead-Scientist Chemistry &
Formulation

Generates Proof



Soon to be filled
Lead-Scientist Preclinical



Prof. Dr. Frauke Alves
Founder

Drives Pharma Licensing



Verena Arendt
Company Building/Strategy



Advisor: Dr. Markus Lang
Development Strategy



Advisor: Dr. Michael Ruppert
Business Development Director



Better Delivery With Our Nanoparticles

Website



Linked-in

